Occudo Quantitative Strategies’s Anika Therapeutics ANIK Stock Holding History

Occudo Quantitative Strategies’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$195K	Sell	15,687 -9,823	-39%	-$114K	0.01%	675
2025 Q4	$245K	Buy	25,510 +15,407	+152%	+$148K	0.02%	544
2025 Q3	$95K	Buy	+10,103	New	+$96.5K	0.01%	625
2024 Q1	–	Sell	-10,924	Closed	-$248K	–	723
2023 Q4	$248K	Buy	+10,924	New	+$226K	0.03%	589
2023 Q3	–	Sell	-11,600	Closed	-$301K	–	957
2023 Q2	$301K	Buy	+11,600	New	+$310K	0.03%	736

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Occudo Quantitative Strategies's ANIK Position: Q1 2026 in Review

Occudo Quantitative Strategies reduced its Anika Therapeutics (ANIK) stake by 39% in Q1 2026, selling an estimated $114K and leaving 15,687 shares worth $195K. The position accounts for 0.01% of the portfolio, ranked #675.

Occudo Quantitative Strategies first reported a position in ANIK in Q2 2023 and has held it in 5 quarters since. The position peaked at $301K in Q2 2023. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

Occudo Quantitative Strategies held 15,687 shares of Anika Therapeutics worth $195K as of Q1 2026.
Occudo Quantitative Strategies sold 9,823 Anika Therapeutics shares in Q1 2026, an estimated $114K.
Anika Therapeutics made up 0.01% of Occudo Quantitative Strategies's portfolio in Q1 2026, its #675 holding.
Occudo Quantitative Strategies first reported a position in Anika Therapeutics in Q2 2023 and has held it in 5 quarters since.
Occudo Quantitative Strategies's Anika Therapeutics position peaked at $301K in Q2 2023.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2026, filed 15 May 2026.